ArticleMolecular cancer therapeutics2019

Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention.

Susan R Mallery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.